Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy

Выживаемость при первичной легочной гипертензии
Vallerie V. McLaughlin, Stuart Rich, Alicia C. Shillington
2002-09-16

intravenous epoprostenollong-term survivalprimary pulmonary hypertensionpulmonary hemodynamicsvasodilator response
BACKGROUND: Primary pulmonary hypertension (PPH) is a severe and progressive disease. Without treatment, the median survival is 2.8 years, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 years, respectively. Intravenous epoprostenol was the first Food and Drug Administration-approved therapy for PPH. The long-term impact that epoprostenol has made on PPH remains to be defined. METHODS AND RESULTS: One hundred sixty-two consecutive patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 months (median, 31 months). Data including functional class, exercise tolerance, and hemodynamics were recorded in a customized database. Vital status was verified in each patient. Observed survival with epoprostenol therapy at 1, 2, and 3 years was 87.8%, 76.3%, and 62.8% and was significantly greater than the expected survival of 58.9%, 46.3%, and 35.4% based on historical data. Baseline predictors of survival included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine. Predictors of survival after the first year of therapy included functional class and improvement in exercise tolerance, cardiac index, and mean pulmonary artery pressure. CONCLUSIONS: Intravenous epoprostenol improves long-term survival in PPH.
1
After the first year, survival was predicted by functional class and improvements in exercise tolerance, cardiac index, and mean pulmonary artery pressure.
2
Among 162 epoprostenol-treated patients, observed survival was 87.8% at 1 year, 76.3% at 2 years, and 62.8% at 3 years.
3
Baseline survival predictors included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine.
4
Historical expected survival was substantially lower: 58.9% at 1 year, 46.3% at 2 years, and 35.4% at 3 years.
5
Intravenous epoprostenol significantly improved survival in primary pulmonary hypertension compared with historical untreated outcomes.

Patients with primary pulmonary hypertension treated with intravenous epoprostenol

Long-term survival and its clinical, functional, and hemodynamic predictors

Publication Details
Publication Date
2002-09-16
Journal
Publisher
ISSN
Cited by
1219
Access Type
Author Information
Authors
Vallerie V. McLaughlin
Stuart Rich
Alicia C. Shillington
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%